Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Middle District of Tennessee on behalf of shareholders of Ardent Health, Inc. who purchased shares between July 18, 2024 and November 12, 2025.
Ardent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 12, 2025, post-market, the Company disclosed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after the Company transitioned to a new revenue accounting system and from purported “recently completed hindsight evaluations of historical collection trends.” The Company further disclosed a cut to 2025 EBITDA guidance of $57.5 million at the midpoint, or about 9.6%, from $575 million – $625 million to $530 million – $555 million due to “persistent industry-wide cost pressures,” including “payer denials,” and also recorded a $54 million increase in professional liability reserves “with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and 2022 in New Mexico” as well as “consideration of broader industry trends, including social inflationary pressures.”
On this news, the price of Ardent’s shares fell $4.75 per share, or nearly 34%, from $14.05 per share on November 12, 2025, to close at $9.30 per share on November 13, 2025, on unusually heavy trading volume.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until March 9, 2026 to request that the court appoint them lead plaintiff.